Paul Bolno
Principal executive officer pay for Paul Bolno, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Wave Life Sciences Ltd. (WVE) FY2021–FY2024
Beat peersTSR 294% vs peer group -54% over FY2021–FY2024
Turnaround$100 invested moved from behind the peer group ($39.90 vs $76.00) to ahead ($157.18 vs $34.94) over FY2021–FY2024
Aligned: paid up as stock roseCAP $1,265,141→$17,389,937 while $100 invested went $39.90→$157.18
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $3.9M | $1.3M |
| FY2022 | $2.7M | $6.1M |
| FY2023 | $3.9M | $2.2M |
| FY2024 | $4.3M | $17.4M |
The company's "$100 invested" index ran $39.90 at FY2021 → $157.18 by FY2024 — an annualized return of 57.9%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 57.9%/yr at WVE ( FY2021–FY2024). See the CEO track-record ranking for context.